Recently, Gansané and colleagues published an article on inadequate efficacy of two different forms of artemisinin-based combination therapy (ACT) in Burkina Faso. The development of Plasmodium falciparum resistance to different ACT partner drugs at levels that could affect the efficacy of two ACT would both be startling and a cause for great concern. In reviewing the available data collected since 2008 on ACT efficacy in Burkina Faso, the analysis shows that the reported efficacy of the tested ACT varies greatly. Most of the studies have considerable methodological deviations and challenges, especially in PCR correction done to distinguish between recrudescence and re-infection, and in the failure to omit re-infections in the calculation of efficacy rates. So far, there is no convincing evidence in the articles reviewed that multidrug resistance has emerged in Burkina Faso. However, the potential consequence of failing ACT means that the results published by Gansané et al. urgently need to be confirmed. Furthermore, articles reporting on efficacy data need to include an examination of the potential consequences of any methodological deviations.

中文翻译：

---

布基纳法索是否有抗疟疾多重耐药性的证据？

最近，Gansané 及其同事发表了一篇关于布基纳法索两种不同形式的青蒿素联合疗法 (ACT) 疗效不足的文章。恶性疟原虫对不同 ACT 伙伴药物的耐药性的发展水平可能会影响两种 ACT 的疗效，这既令人震惊，又引起了极大的关注。在审查自 2008 年以来在布基纳法索收集的有关 ACT 功效的可用数据时，分析表明所报告的 ACT 测试功效差异很大。大多数研究都有相当大的方法偏差和挑战，特别是在为区分复发和再感染而进行的 PCR 校正方面，以及在计算有效率时未能忽略再感染。迄今为止，所审查的文章中没有令人信服的证据表明布基纳法索出现了多药耐药性。然而，ACT 失败的潜在后果意味着 Gansané 等人发表的结果。急需确认。此外，报告功效数据的文章需要包括对任何方法偏差的潜在后果的检查。